Inflammatory Bowel Disease

New ACG 2024 data show patients with both IBD and vitamin D deficiency face longer, more expensive hospital stays, as well as risk of colectomy.

Solomon explains how to navigate the growing Crohn disease treatment armamentarium and the importance of treatment positioning.

The decision is based on rates of clinical and endoscopic remission with guselkumab in the ongoing phase 2b/3 QUASAR study.

The HCPLive August gastroenterology month in review spotlights expansions in gastrointestinal treatment and screening access as well as the newest edition of Qazi Corner.

AHN Division of Gastroenterology, Hepatology, and Nutrition addresses patients’ challenging symptoms and needs with wide-ranging strategies and innovative treatments.

Medical experts in inflammatory bowel disease discuss the current evidence on dual advanced therapy for ulcerative colitis and Crohn's disease, highlighting the potential benefits, while also addressing the challenges and complexity of treatment management.

Gastroenterologist experts discuss the current landscape of biologic treatments for inflammatory bowel disease and the occasional necessity to switch between different biologic agents, while also sharing insights on their preferred treatment sequencing strategies.

The July 2024 gastroenterology month in review highlights FDA news, GI pipeline updates, and a new clinical practice update from the American Gastroenterological Assocation.

Silvio Danese, MD, PhD; Bruce Sands, MD, and Jean-Frederic Colombel, MD, highlight the common practice in many community settings of treating inflammatory bowel disease (IBD) with corticosteroids, with or without 5-aminosalicylic acid, and cycling patients through this regimen for prolonged periods, while emphasizing the significant impact and toxicities associated with this treatment approach.

Silvio Danese, MD, PhD; Bruce Sands, MD, and Jean-Frederic Colombel, MD highlight the common practice in many community settings of treating inflammatory bowel disease with corticosteroids, with or without 5-aminosalicylic acid, and cycling patients through this regimen for prolonged periods, while emphasizing the significant impact and toxicities associated with this treatment approach.

The phase 2 trial did not meet its primary endpoint for mean change in Crohn’s disease activity index in either VTX958 dosing group.

Data from INSPIRE and COMMAND were used to support risankizumab’s FDA approval for ulcerative colitis, demonstrating the IL-23 inhibitor’s impact on clinical remission.

Expert panelists discuss the implementation of a treat-to-target approach for the long-term management of inflammatory bowel disease (IBD), drawing upon data from the STARDUST and REACT-2 trials to support their recommendations and insights into optimizing patient outcomes through this strategy.

Expert gastroenterologists delve into the concept of transmural healing as a treatment target for both ulcerative colitis and Crohn's disease, sharing insights on their preferred timeframes for reassessing treatment progress, monitoring methods, and the effectiveness of intestinal ultrasounds in the management of these conditions.

The June 2024 gastroenterology month in review highlights FDA news and other pipeline developments in GI as well as the publication of the latest installment of Qazi Corner.

Findings from a post hoc analysis of True North and its open-label extension highlight ozanimod’s rapid onset of action and durability in advanced therapy-naive patients with UC.

Loftus explains the significance of IL-23 and Th17 in IBD and key trial data supporting the FDA approval of risankizumab in ulcerative colitis.

Positive topline results showed guselkumab (Tremfya) SC induction therapy met all primary and secondary endpoints, suggesting similar clinical benefit to IV induction seen in GALAXI.

The approval is based on data from a pair of phase 3 studies and makes risankizumab-rzaa the first IL-23 specific inhibitor approved for both ulcerative colitis and Crohn’s disease.

Silvio Danese, MD, PhD; Bruce Sands, MD, and Jean-Frederic Colombel, MD, discuss their preferred recommended targets for managing ulcerative colitis (UC) or Crohn's disease (CD), emphasizing the aggressive approach required to achieve these targets effectively.

Medical experts in inflammatory bowel disease (IBD) define the concept of "treat-to-target" within the context of IBD and provide current recommendations on treatment targets for ulcerative colitis and Crohn's disease, the two main forms of IBD.

Qazi discusses implications from a recent study exploring the impact of post-IPAA cuffitis on long-term pouch outcomes and the risk of developing strictures and fistulas.

The May 2024 gastroenterology month in review spotlights top research from Digestive Disease Week 2024 and the FDA approval of ColoSense.

Sands reviews key findings from the phase 3 VIVID-1 study of mirikizumab in Crohn’s disease presented at DDW.

In honor of World Digestive Health Day, this feature examines the growth of intestinal ultrasound in IBD care in the US and how it aligns with STRIDE-II guidance.

Krugliak Cleveland explains findings from research she presented at DDW comparing intestinal ultrasound and conventional approaches to disease monitoring in IBD.

Panaccione explains findings from GALAXI 2 and GALAXI 3 demonstrating guselkumab’s superiority to ustekinumab in Crohn’s disease, presented at DDW.

Both doses of guselkumab exhibited statistical superiority on all prespecified pooled endoscopic endpoints versus ustekinumab in Crohn's disease.

The phase 3 QUASAR Maintenance study met its primary endpoint of clinical remission and demonstrated statistically significant endoscopic remission rates in UC treatment.

Sehgal explains the safety and efficacy of GLP-1RAs in patients with IBD as well as the impact on inflammatory biomarkers.